Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm — NODE-1  

Paroxysmal Supraventricular Tachycardia (PSVT) Clinical Trial

Official title: Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm

Status Completed

Clinical Trial Summary

The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Clinical Trial Description

This is a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the effects of 4 different doses of MSP-2017 (Etripamil) in subjects with paroxysmal supraventricular tachycardia. It includes an up to 21-day Screening Period, a 1-day Treatment Visit, and either a Follow-up Visit or Early Termination Visit occurring 12 hours to 5 days after the Treatment Visit. Subjects will be randomized to yield at least 100 evaluable subjects distributed into 5 groups of at least 20 subjects each. ;

Related Conditions & MeSH terms

• Paroxysmal Supraventricular Tachycardia (PSVT)
• Tachycardia
• Tachycardia, Supraventricular

• NCT number: NCT02296190
• Study type: Interventional
• Source: Milestone Pharmaceuticals Inc.
• Status: Completed
• Phase: Phase 2
• Start date: March 27, 2015
• Completion date: December 2016